Observations on the therapy of acute infectious hepatitis with Liv.52

Shishupal Ram, M.D., M.R.C.P., D.C.H. (Lond.), and Kumar, P., Research Scholar, Liver Research Unit, Hospital for Children, Patna Medical College Hospital, Patna, India.

The liver holds a place of singular importance in maintaining human health. It controls numerous metabolic processes via the metabolic pool. Diseases of the liver have adverse effects on the entire system. Any drug that would help the hepatic function would be of great value to clinicians. There have been remarkable contributions to research and therapeutics but as yet, in allopathic medicine, there is no drug that stimulates the functions of the liver, protects it from damage or helps in the regeneration of hepatic cells.

Many published studies have reported favourably on the clinical and therapeutic response to Liv.52 (Himalaya Drug Co., Pvt Ltd.), in a wide variety of hepatic disorders. This study was undertaken to determine the therapeutic effects of Liv.52 in infectious hepatitis.


The study was carried out at the Hospital for children, Prince of Wales Patna Medical College and its out-patient department.

All the children in the study were admitted in the hospital. Their detailed history was taken and a thorough physical examination was done according to a previously planned proforma. They were subjected to routine investigations along with some specific biochemical tests for liver disorders. These were plasma proteins, serum alkaline phosphatase, thymol turbidity, serum bilirubin and SGPT. The children were given Liv.52 in adequate doses along with the usual general management of diet and nursing.

There were 36 cases of infectious hepatitis studied. Out of these there were 3 cases of subacute hepatic necrosis.
Age Distribution
Age No. of cases
1 – 5 years

12 cases

6 – 10 years

19 cases

11–12 years

5 cases

Sex distribution was almost equal with slight preponderance of males.


Symptoms No. of cases
Tinging of conjunctiva 36
Yellow coloured urine 32
Loss of appetite 32
Digestive upset 30
Nausea or vomiting 23
Pain in abdomen 20
Irritability 20
Oedema legs 3
Signs No. of signs
Jaundice 36
Enlarged liver 32
Tender liver 21
Pallor 17
Oedema 3
Ascites 1

The laboratory investigations revealed the following:

Serum Proteins

No. of cases

Less than 4 g%


Less than 4 – 5 g%


Less than 5 – 6 g%


Over 6 g%



Serum Bilirubin

No. of cases

1 – 5 mg%


6 – 10 mg%


11 – 15 mg%



SGPT Levels

No. of cases

Less than 100 units


101 – 200 units


201 – 300 units


Over 300 units



The progress and response were noted clinically as well as by response to the laboratory tests and the jaundice gradually cleared up, appetite returned, liver tenderness gradually became less and the patients gradually recovered. Serum bilirubin and SGPT levels gradually but remarkably came down along with the clinical improvement. Blood proteins were not disturbed in some cases but where they were they took longer to return to normal.

Out of 36 patients one expired and the remaining 35 recovered. They were followed up and discharged as cured.


1. Thirty six cases of Infectious Hepatitis were studied at Patna Medical College Hospital for the therapeutic effects of Liv.52.

2. Clinical and laboratory studies were made and progress was noted.

3. There was remarkable clinical and laboratory response towards recovery.

4. Thirty five patients were discharged cured and one expired.

Our conclusions are totally based upon our observations presented here. Liv.52 has a definite role in improving the clinical condition and appetite.

Refference: http://www.himalayahealthcare.com/pdf_files/liv216.pdf
free delivery Liv 52
Copyrights © 2009 healthyliver.co.uk